AJMC - Change is Coming
|Articles|October 1, 2002

Supplements and Featured Publications

  • Cardiorenal Differences Among NSAIDs and Coxibs: Real-World Experience
  • Volume 8
  • Issue 15 Suppl

Differences Between COX-2-Specific Inhibitors: Clinical and Economic Implications

Download PDF: Differences Between COX-2-Specific Inhibitors: Clinical and Economic Implications

Articles in this issue

over 23 years ago

Participating Faculty

over 23 years ago

Cardiorenal Differences Among NSAIDs and Coxibs: Real-World Experience

over 23 years ago

Cyclooxygenase-2-Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis Patients

over 23 years ago

Prevalence of Cardiovascular Disease Risk Factors Among US Adults With Self-Reported Osteoarthritis: Data from the Third National Health and Nutrition Examination Survey

over 23 years ago

Comparison of the Baseline Cardiovascular Risk Profile Among Hypertensive Patients Prescribed COX-2-Specific Inhibitors or Nonspecific NSAIDs: Data From Real-Life Practice

over 23 years ago

Blood Pressure Destabilization and Related Healthcare Utilization Among Hypertensive Patients Using Nonspecific NSAIDs and COX-2-Specific Inhibitors

over 23 years ago

Cost of Heart Failure Among Hypertensive Users of Nonspecific NSAIDs and COX-2-Specific Inhibitors

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs
Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

View more
Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo
Alt TextAlt Text